These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24266428)

  • 1. Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution.
    Jimenez-Zepeda VH; Franke N; Reece DE; Trudel S; Chen C; Delgado DH; Winter A; Mikhael JR; Tiedemann R; Kukreti V
    Br J Haematol; 2014 Mar; 164(5):722-8. PubMed ID: 24266428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study.
    Vesole DH; Pérez WS; Akasheh M; Boudreau C; Reece DE; Bredeson CN;
    Mayo Clin Proc; 2006 Jul; 81(7):880-8. PubMed ID: 16835967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
    Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
    Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis.
    Gertz MA; Lacy MQ; Dispenzieri A; Kumar SK; Dingli D; Leung N; Hogan WJ; Buadi FK; Hayman SR
    Bone Marrow Transplant; 2013 Apr; 48(4):557-61. PubMed ID: 22964596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome.
    Mollee PN; Wechalekar AD; Pereira DL; Franke N; Reece D; Chen C; Stewart AK
    Bone Marrow Transplant; 2004 Feb; 33(3):271-7. PubMed ID: 14647248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
    Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.
    Perfetti V; Siena S; Palladini G; Bregni M; Di Nicola M; Obici L; Magni M; Brunetti L; Gianni AM; Merlini G
    Haematologica; 2006 Dec; 91(12):1635-43. PubMed ID: 17145600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
    Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
    Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP.
    Hayashi T; Ikeda H; Igarashi T; Maruyama Y; Aoki Y; Nojima M; Ishida T; Shinomura Y
    Int J Hematol; 2014 Dec; 100(6):554-8. PubMed ID: 25281404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
    Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
    Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum uric acid: novel prognostic factor in primary systemic amyloidosis.
    Kumar S; Dispenzieri A; Lacy MQ; Hayman SR; Leung N; Zeldenrust SR; Buadi FK; Kyle RA; Rajkumar SV; Gertz MA
    Mayo Clin Proc; 2008 Mar; 83(3):297-303. PubMed ID: 18315995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate.
    Gertz MA; Lacy MQ; Dispenzieri A; Ansell SM; Elliott MA; Gastineau DA; Inwards DJ; Micallef IN; Porrata LF; Tefferi A; Litzow MR
    Bone Marrow Transplant; 2004 Dec; 34(12):1025-31. PubMed ID: 15516945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single-centre cohort of patients with systemic light chain AL-amyloidosis treated with conventional chemotherapy or with high-dose chemotherapy and autologous stem cell transplantation.
    Raschle J; Banz Y; Suter T; Pabst T
    Swiss Med Wkly; 2014 Feb; 144():w13922. PubMed ID: 24554372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience.
    Chow LQ; Bahlis N; Russell J; Chaudhry A; Morris D; Brown C; Stewart DA
    Bone Marrow Transplant; 2005 Oct; 36(7):591-6. PubMed ID: 16062177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Jaccard A; Moreau P; Leblond V; Leleu X; Benboubker L; Hermine O; Recher C; Asli B; Lioure B; Royer B; Jardin F; Bridoux F; Grosbois B; Jaubert J; Piette JC; Ronco P; Quet F; Cogne M; Fermand JP;
    N Engl J Med; 2007 Sep; 357(11):1083-93. PubMed ID: 17855669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial.
    Sanchorawala V; Wright DG; Seldin DC; Falk RH; Finn KT; Dember LM; Berk JL; Quillen K; Anderson JJ; Comenzo RL; Skinner M
    Bone Marrow Transplant; 2004 Feb; 33(4):381-8. PubMed ID: 14676787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Heart transplantation and follow-up treatment with AL-amyloidosis in 5 patients].
    Adam Z; Ozábalová E; Němec P; Bedáňová H; Kuman M; Krejčí J; Špinarová L; Žampachová V; Čermáková Z; Pour L; Krejčí M; Sanecká V; Štork M; Pika T; Straub J; Adamová D; Stavařová Y; Král Z; Mayer J
    Vnitr Lek; 2018; 64(4):441-449. PubMed ID: 29791180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decrease of B-type natriuretic peptide to less than 200 pg/mL predicts longer survival in cardiac immunoglobulin light chain amyloidosis.
    Ishiguro K; Hayashi T; Igarashi T; Maruyama Y; Ikeda H; Ishida T; Shinomura Y
    Int J Hematol; 2015 Aug; 102(2):200-4. PubMed ID: 26016720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.